Yahoo!
My Yahoo!
Mail
Sign In
[New User?
Sign Up
]
Finance Home
|
Help
Wednesday, February 10, 2010, 8:42am EST - Canadian Markets open in 48 minutes.
To create a watchlist or portfolio of shares,
Sign-in
or
Register
Finance Home
Investing
Volume Leaders
Local Markets
US Markets
International Markets
Advances & Declines
ETFs
Income Trust News
News & Opinion
Markets
Industry
RSS-My Yahoo!
Personal Finance
Banking & Budgeting
Calculators
Insurance
Retirement
Taxes
My Portfolios
Sign In to Create/Edit My Portfolios
Get Quotes
Symbol Lookup
Exchanges
MDRNA, Inc. (MRNA)
On Feb 9:
0.8949 USD
0.00 (0.00%)
MORE ON MRNA
Quotes
Summary
Options
Historical Prices
Charts
Interactive
Basic Chart
Technical Chart
News & Info
Headlines
Company Events
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Analyst Coverage
Analyst Opinion
Analyst Estimates
Research Reports
Star Analysts
Ownership
Major Holders
Insider Trans.
Insider Roster
Financials
Income Statement
Balance Sheets
Cash Flow
MDRNA, Inc.
(NGM:MRNA) Delayed quote data
Last Trade:
0.8949 USD
Trade Time:
Feb 9
Change:
0.00 (0.00%)
Prev Close:
0.8949
Open:
N/A
Bid:
0.83
x 200
Ask:
0.994
x 25000
1y Target Est:
3.00
Day's Range:
N/A - N/A
52wk Range:
0.22 - 3.55
Volume:
0
Avg Vol
(3m)
:
1,451,510
Market Cap:
36.48M
P/E
(ttm)
:
N/A
EPS
(ttm)
:
-0.558
Div & Yield:
N/A (N/A%)
1d
5d
3m
6m
1y
2y
5y
max
Add MRNA to Portfolio
Download Data
HEADLINES
MDRNA, Inc. Reports Positive Results for Its Proprietary siRNA Delivery Technology
Marketwire
(Mon, Feb 8)
MDRNA, Inc. Receives Compliance Extension From NASDAQ
Marketwire
(Mon, Feb 8)
MDRNA, Inc. to Present at the 12th Annual BIO CEO & Investor Conference
Marketwire
(Mon, Feb 1)
Sirius XM, Tellabs: Early Volume Plays
at TheStreet.com
(Tue, Jan 26)
MDRNA, Inc. Issued Patent for the Use of Nucleic Acids to Treat Cancer
Marketwire
(Tue, Jan 26)
MDRNA, Inc. Announces Allowance of European Patent Covering Formulations for Rapid Acting Insulin
Marketwire
(Thu, Jan 21)
This Drugmaker Will Rally by Summer: Investors
at CNBC
(Wed, Jan 20)
MDRNA Draws Bullish Options Trade
at TheStreet.com
(Wed, Jan 20)
Ballard Power, Enterra: Early Volume Plays
at TheStreet.com
(Tue, Jan 19)
MDRNA Demonstrates Significantly Reduced Off-Target Activity for Proprietary RNAi-Based Compounds
Marketwire
(Tue, Jan 19)
More Headlines for MRNA...
ANALYST
EPS Est (next year)
(Dec-09)
:
-0.38
EPS Est (in 2 years)
(Dec-10)
:
-0.33
Avg Rec (current)*:
2.5
PEG Ratio:
N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion
-
Estimates
BUSINESS SUMMARY
MDRNA, Inc. operates as a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi).
Full Company Profile
Add to Portfolio
Email to a Friend
Get
Summary
for Another Symbol:
Symbol Lookup
Latest News
Canadian Indices